J Immunol 2002, 169:2164–2171.PubMed 19. Fujiwara H, Melenhorst JJ, El Ouriaghli F, Kajigaya S, Grube M, Sconocchia G, Rezvani K, Price DA, Hensel NF, Douek DC, Barrett AJ: In vitro induction of myeloid leukemia-specific CD4 and CD8 T cells by CD40 ligand-activated B cells gene modified to express primary granule proteins. Clin Cancer Res 2005, 11:4495–4503.PubMedCrossRef 20. von Bergwelt-Baildon MS, Vonderheide RH, Maecker B, Hirano N, Anderson KS, Butler MO, Xia Z, Zeng WY, Wucherpfennig KW, Nadler LM, Schultze JL: Human primary

and S63845 concentration memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application. Blood 2002, 99:3319–3325.PubMedCrossRef 21. Coughlin CM, Vance BA, Grupp SA, Vonderheide RH: RNA-transfected CD40-activated B cells induce functional AMN-107 mw T-cell

responses against viral and tumor antigen targets: implications for pediatric immunotherapy. Blood 2004, 103:2046–2054.PubMedCrossRef 22. Guo S, Xu J, Denning W, Hel Z: Induction of protective cytotoxic T-cell responses by a B-cell-based cellular vaccine requires stable expression of antigen. Gene Ther 2009, 16:1300–1313.PubMedCrossRef 23. Kim SK, Nguyen Pham TN, Nguyen Hoang TM, Kang HK, Jin CJ, Nam JH, Chung SY, Choi SJ, Yang DH, Kim YK, et al.: Induction of myeloma-specific cytotoxic T lymphocytes ex vivo by CD40-activated B cells loaded with myeloma tumor antigens. Ann Hematol 2009, 88:1113–1123.PubMedCrossRef 24. Lee J, Dollins CM, Boczkowski D, Sullenger BA, Nair S: Activated B cells modified by electroporation of multiple mRNAs encoding immune stimulatory molecules are comparable to mature dendritic cells in inducing in vitro also antigen-specific T-cell responses. Immunology 2008, 125:229–240.PubMedCrossRef 25. Mason NJ, Coughlin CM, Overley B, Cohen JN, Mitchell EL, Colligon TA, Clifford CA, Zurbriggen A, Sorenmo KU, Vonderheide RH: RNA-loaded

CD40-activated B cells stimulate antigen-specific T-cell responses in dogs with spontaneous lymphoma. Gene Ther 2008, 15:955–965.PubMedCrossRef 26. Shen SN, Xu Z, Qian XP, Ding YT, Yu LX, Liu BR: RNA-electroporated CD40-activated B cells induce functional T-cell responses against HepG2 cells. Eur J Cancer Care (Engl) 2008, 17:404–411.CrossRef 27. Sorenmo KU, Krick E, Coughlin CM, Overley B, Gregor TP, Vonderheide RH, Mason NJ: CD40-activated B cell cancer vaccine improves second clinical remission and LY3023414 manufacturer survival in privately owned dogs with non-Hodgkin’s lymphoma. PLoS One 2011, 6:e24167.PubMedCrossRef 28. Kondo E, Gryschok L, Klein-Gonzalez N, Rademacher S, Weihrauch MR, Liebig T, Shimabukuro-Vornhagen A, Kochanek M, Draube A, von Bergwelt-Baildon MS: CD40-activated B cells can be generated in high number and purity in cancer patients: analysis of immunogenicity and homing potential. Clin Exp Immunol 2009, 155:249–256.PubMedCrossRef 29.